Connect with us

Emerging Markets

Innerscope Hearing Technologies Inc (OTCMKTS: INND) Move Northbound Brewing on iHEAR Acquisition & LOI to Acquire Hearing Assist LLC

Published

on

InnerScope Hearing Technologies, Inc. (OTC PINK: INND) is racing up the charts after the Company announced an LOI to acquire Hearing Assist II LLC and is expected to close on Nov. 15, 2021. HearingAssist has sold more than 500,000 hearing aids to nearly 400,000 customers via direct-to-consumer or through retail partners. They were the first direct-to-consumer hearing aid company to use mass national television marketing to create a recognizable brand as America’s #1 Affordable Hearing Brand. Since HearingAssist launched its acclaimed television spot in April 2018 on major national TV networks, it has generated more than $72 million of top-line revenue through July 2021. HearingAssist’s products are currently displayed in over 757 Walmart’s in five states. In addition, HearingAssist has multiple vendor contracts signed and expansions currently underway with Walmart and other retailers. With the expected Over-the-Counter Law coming into effect in 2022, HearingAssist brand revenue projections are expected to exceed $150 million annualized by 2024. 

INND is an investors favorite that is getting noticed by some big players as the Company launches its latest breakthroughs in Hearing Technology with its New Smartphone Controlled Direct-to-Consumer Self-Fitting-Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. InnerScope is a wholesale vendor for Walmart and was recently accepted into BJ’s Wholesale Club operating 215+ Locations in 17 States. INND has seen tremendous growth through acquisition recently acquiring iHEAR Medical Inc. based in San Leandro, California. The Acquisition expands InnerScope’s products and services to include the iHEARtest™, the only FDA-Cleared home hearing screener (FDA Clears Home Hearing Test on ABC7 / 2018), advanced FDA-Registered hearing aids, and the TReO™ Personal Sound Amplification Product (PSAP). Assets acquired in the transaction include iHEAR’s FDA-Registered manufacturing facility, R&D center, and shipping operations in San Leandro, California. InnerScope is starting to attract mainstream press including Fox Business News, Bloomberg and a 12-part series by Newsmax. 

InnerScope Hearing Technologies, Inc. (OTC PINK: INND) is a leading manufacturer and distributor of FDA-registered hearing aids, hearing assistive devices, hearing health-related products, and Personal Sound Amplifier Products (PSAPs) (“Hearing Products”) dedicated to addressing the global demand for affordable hearing solutions. InnerScope’s Hearing Products and its business model break through the persistent barriers that prevent access to effective hearing solutions. With the recent Acquisition of iHear Medical Inc., a cloud-based hearing solution provider with access to over 40 patents, and the completion of the Acquisition of HearingAssist, an established leader in the direct-to-consumer hearing aid market for more than 13 years, InnerScope’s is positioned to expand its distribution partnership network and its leadership in the direct-to-consumer hearing solutions market with advanced Hearing Products offered at a fraction of the cost of conventional hearing aids sold in hearing aid centers.  

InnerScope Hearing Technologies (OTC: $INND) on Twitter: "$INND Update: $ INND & NYSE Retailer Joint PR will be out soon. Until then, Basic MUTUAL  Conservative Financial Projection from this ONE Retailer: 60,800 unitsThe Company is led by CEO Matthew Moore who grew up in the hearing health industry, with having internships and mentorships beginning with his Grandfather who has personally helped over 20,000 hearing- impaired patients in his private hearing aid practice since the 1940s. At the age of 10, Matthew was working in the Marketing Department of his parents private hearing aid practice. By the age of 22, Matthew became a full partner in his parents hearing aid business, which then grew to one of the largest private hearing aid practices in the United States with over 70 locations and over 40,000 customers in a 10-year period. Several years ago, the family sold off the remaining locations for $14 million. As CEO of InnerScope, Mr. Moore has been making one big move after another recently forming distribution partnerships with Walmart, Sears, and other Big Box Retailers/Pharmacies as well as independent retailers and pharmacies for InnerScope’s Products and Services.   

INND operates in the booming hearing aids space; According to a report from Fortune Business Insights the global hearing aids market is set to gain impetus from the increasing adoption of telehealth among audiologists to prevent patient traffic. The report further states that the market size was USD 8.99 billion in 2019 and is projected to reach USD 13.38 billion by 2027, exhibiting a CAGR of 8.2% during the forecast period.   

The Company launched its hearIQ App in 172 countries in the Apple App Store for iOS devices and Google Play Store for Android devices. The hearIQ App is a multi-functional app, which offers to the general public a FREE Self-Administered Hearing Test to determine hearing loss (if any) and also provides a Bluetooth wireless connection (“App Controlled”) for InnerScope’s Direct-to-Consumer Self-Fitting-Self-Adjusting Hearing Aids. The hearIQ App is specifically designed to help with early detection of hearing loss for the 48+ million Americans as well as the 1.5 billion people worldwide who may have an undetected hearing loss or may be living with some degree of hearing loss, according to the World Health Organization (“WHO”). More importantly, if hearing loss is detected, the hearIQ App directly links to InnerScope’s Direct-to-Consumer Hearing Products. Since the hearIQ App became activated only nine days ago, it has already received over 440 reviews and has a FIVE-STAR RATING from Apple and Android users.  

  

To Find out the inside Scoop on INND Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

INND

INND is rapidly growing through acquisition; in October they acquired all assets and operations of iHEAR Medical Inc. based in San Leandro, California. iHEAR, founded in 2010, pioneered online direct-to-consumer hearing solutions (iHear Medical on ABC7 KGO / 2013). The Acquisition bolsters InnerScope’s position as the leader in the emerging market of direct-to-consumer (“DTC”) and over-the-counter (“OTC”) hearing products. The Acquisition expands InnerScope’s products and services to include the iHEARtest™, the only FDA-Cleared home hearing screener (FDA Clears Home Hearing Test on ABC7 / 2018), advanced FDA-Registered hearing aids, and the TReO™ Personal Sound Amplification Product (PSAP). The Acquisition also expands InnerScope’s customer base and provides access to iHEAR’s established retail and contracted distribution channels. Assets acquired in the transaction include iHEAR’s FDA-Registered manufacturing facility, R&D center, and shipping operations in San Leandro, California. 

INND is making an explosive move northbound after the Company announced it has entered into an LOI to acquire 100% of the equity in Hearing Assist II LLC. The LOI was executed on Oct. 19, 2021, and currently, InnerScope and HearingAssist are working on the definitive agreement with the expected close date of Nov. 15, 2021. HearingAssist has sold more than 500,000 hearing aids to nearly 400,000 customers via direct-to-consumer or through retail partners. HearingAssist was the first direct-to-consumer hearing aid company to use mass national television marketing to create a recognizable brand as America’s #1 Affordable Hearing Brand. Since HearingAssist launched its acclaimed television spot in April 2018 on major national TV networks, it has generated more than $72 million of top-line revenue through July 2021. HearingAssist’s products are currently displayed in over 757 Walmart’s in five states. In addition, HearingAssist has multiple vendor contracts signed and expansions currently underway with Walmart and other retailers. With the expected Over-the-Counter Law coming into effect in 2022, HearingAssist brand revenue projections are expected to exceed $150 million annualized by 2024. 

HearingAssist has a full lineup of affordable, high-quality rechargeable hearing aids, a digital TV listener device, and various hearing aid accessories. In addition, HearingAssist also has an exclusive intellectual property right to distribute and the option to purchase two patents for its hearing aids. 

InnerScope expects the Acquisition of HearingAssist, its management team, proven sales track record, strategic contracts with numerous major retailers, and the national marketing campaign to elevate InnerScope as the number one direct-to-consumer hearing aid sales company in the market. Moreover, with InnerScope’s recent Acquisition of iHear Medical Inc. and its experienced research and development team, its FDA-Registered hearing aid manufacturing facility and its 40+ patents strengthen InnerScope’s competitive edge over all other DTC / OTC companies. The Acquisition of HearingAssist and iHear Medical Inc. completes InnerScope’s business model strategy by integrating “Big Box” wholesale/retail distribution partners with its innovated patented proprietary Hearing Products. 

Mr. Matthew Moore, President, and CEO of InnerScope went on to state: “InnerScope and its management team are excited about the Acquisition of HearingAssist. The Acquisition will leverage our combined expertise and resources to accelerate our business development to the next level. InnerScope’s management team has strived to build a company that can compete with the “Big-Five” global manufactures, which control 98% of all hearing aids sold of the $10+ billion-dollar market. We believe that the Acquisitions of HearingAssist and iHear Medical Inc. has positioned InnerScope to bring innovative patentable hearing technology to market, which will directly compete with the “Big-Five” in market share. We also expect the Acquisition of HearingAssist from the strategic placement of the product display located inside 757 Walmart stores will generate immediate sales revenue for InnerScope.” 

For More on INND Subscribe Right Now!

INND is racing up the charts after the Company announced an LOI to acquire Hearing Assist II LLC and is expected to close on Nov. 15, 2021. HearingAssist has sold more than 500,000 hearing aids to nearly 400,000 customers via direct-to-consumer or through retail partners. They were the first direct-to-consumer hearing aid company to use mass national television marketing to create a recognizable brand as America’s #1 Affordable Hearing Brand. Since HearingAssist launched its acclaimed television spot in April 2018 on major national TV networks, it has generated more than $72 million of top-line revenue through July 2021. HearingAssist’s products are currently displayed in over 757 Walmart’s in five states. In addition, HearingAssist has multiple vendor contracts signed and expansions currently underway with Walmart and other retailers. With the expected Over-the-Counter Law coming into effect in 2022, HearingAssist brand revenue projections are expected to exceed $150 million annualized by 2024.  INND is an investors favorite that is getting noticed by some big players as the Company launches its latest breakthroughs in Hearing Technology with its New Smartphone Controlled Direct-to-Consumer Self-Fitting-Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. InnerScope is a wholesale vendor for Walmart and was recently accepted into BJ’s Wholesale Club operating 215+ Locations in 17 States. INND has seen tremendous growth through acquisition recently acquiring iHEAR Medical Inc. based in San Leandro, California. The Acquisition expands InnerScope’s products and services to include the iHEARtest™, the only FDA-Cleared home hearing screener (FDA Clears Home Hearing Test on ABC7 / 2018), advanced FDA-Registered hearing aids, and the TReO™ Personal Sound Amplification Product (PSAP). Assets acquired in the transaction include iHEAR’s FDA-Registered manufacturing facility, R&D center, and shipping operations in San Leandro, California. InnerScope is starting to attract mainstream press including Fox Business News, Bloomberg and a 12-part series by Newsmax.p Microcapdaily has been reporting on INND since February. We will be updating on INND when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with INND.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in INND either long or short and we have not been compensated for this article

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

on

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

on

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Emerging Markets

GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing

Published

on

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12.

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12. This represents an impressive 137% increase; the volume has been off the hook. If you look at their historical chart, $GSIT had meager volume, sometimes as low as 300 shares traded in a day. If you do the math, that’s less than $500 worth of shares traded in a day – safe to say it was virtually illiquid.

So what happened, and what drove the stock to trade 50M shares with filings or news releases?

After an in-depth examination, GSI Technology, Inc. appears to have experienced a notable turning point in its market trajectory. The catalyst for this transformation was the company’s prominent feature on Fox News, triggering an exponential dissemination of information across various platforms. It is worth highlighting an intriguing phenomenon that tends to transpire in such circumstances: purchasing shares often induces a ripple effect, encouraging further buying activity.

With Fox News bringing the company into the spotlight and stimulating investor interest, a domino effect occurred among astute day traders who eagerly seized the opportunity to partake in this promising venture. Consequently, the trading volume for GSI Technology, Inc. skyrocketed to unprecedented levels, surpassing all previously recorded thresholds.

This surge in volume stands as a testament to the immense enthusiasm that enveloped the market as traders recognized the tremendous potential inherent in $GSIT. This collective enthusiasm resulted in an extraordinary demonstration of market engagement, reflecting a widespread acknowledgment of the company’s significance and the opportunities it presents.

https://twitter.com/SamanthaLaDuc/status/1657033207412293634?s=20

This development showcases the power of influential media coverage and underscores the intriguing dynamics that can arise when investor sentiment aligns with a compelling market narrative.

To Discover the Inside Scoop on GSIT, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Founded in 1995, GSI Technology Inc. has established itself as a prominent provider of semiconductor memory solutions. The company is focused on introducing new products that capitalize on its core strengths, which include radiation-hardened memory products for extreme environments and Gemini, an advanced processing unit (APU) designed to enhance performance in various artificial intelligence (AI) applications. Headquartered in Sunnyvale, California, GSI Technology operates sales offices in the Americas, Europe, and Asia.

GSI Technology is on the verge of reporting its earnings next week, and the company operates in the storage business, which supports the development of highly efficient AI chips. Traditionally, computing involves separate chips for storage and computation, necessitating frequent data exchange. This process incurs significant power consumption and presents scalability challenges.

To address these limitations, GSI Technology has developed a groundbreaking solution called In-memory processing. This innovation substantially reduces computation time from minutes to seconds, milliseconds, or even microseconds. Notably, it also significantly diminishes power consumption and overall cost of ownership. The key to this improvement lies in the massive parallel data processing offered by GSI’s technology, featuring two million-bit processors per chip compared to thousands found in standard graphic processing units (GPUs). Consequently, the system becomes more scalable, enabling efficient and accelerated AI processing.

By streamlining the computing process and integrating storage and computation on a single chip, GSI Technology aims to revolutionize AI processing. This approach offers notable benefits regarding power efficiency, computational speed, and scalability, making it an attractive solution for a wide range of AI applications.

In conclusion, GSI Technology, Inc. is poised to deliver innovative semiconductor memory solutions emphasizing AI chip development. The company aims to reduce computation time, power consumption, and total ownership cost through its In-memory processing technology while significantly improving scalability. With its upcoming earnings report, investors and industry observers will closely watch the company’s progress in the storage business and AI chip development.

We will update you on GSIT when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with GSIT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.